Executive Staff

Tom Rose was named executive vice president and chief operations officer on June 21, 2010. He was named chief fiancial officer for RTI Biologics in February 2008. He also serves as corporate secretary to the board of directors. Rose joined RTI as vice president and CFO in May 2002.

Rose served the previous 10 years as vice president and chief financial officer at A.M. Todd Group, based in Kalamazoo, Mich. Rose earned a bachelor’s degree in business administration from Western Michigan University in Kalamazoo. He has also completed numerous executive education courses at University of Michigan and Northwestern University focusing on strategy and organizational issues.

Roger Rose was named executive vice president and chief commercial officer on June 21, 2010. In February 2008, he was named president of RTI Donor Services, and, in August 2004, he was named executive vice president of RTI. Rose oversees all aspects of the organization’s not-for-profit affiliate, RTI Donor Services, marketing, and the distribution of donated tissue back into the community. He is committed to ensuring a meaningful connection between the donation and transplantation communities.

Rose joined RTI as vice president of donor services in October 2002 and assumed additional responsibility for distribution and marketing in October 2003. Prior to this, Rose spent seven years at Stryker Corporation based in Kalamazoo, Mich., where he held leadership positions in sales and marketing in both the medical and orthopedic divisions.

Rose earned a bachelor’s degree in business administration from Western Michigan University in Kalamazoo and completed numerous executive education courses at UCLA, University of Michigan and Harvard Business School, focusing on finance, leadership, medical marketing, negotiation and strategy.

Carrie Hartill was named executive vice president and chief scientific officer on June 21, 2010. She was named chief scientific officer in March 2007. She joined RTI in November 2001 and was named vice president of quality assurance and regulatory affairs in January 2003. In her role at RTI, Hartill oversees all scientific research, quality assurance, regulatory affairs and clinical studies. She has served as a board member for BioFlorida and is a member of the Advanced Medical Technology Association (AdvaMed). She also serves on the Accreditation Committee and the Strategic Planning Task Force of the American Association of Tissue Banks (AATB). For 18 years prior, she worked in the areas of technology development and market approvals as a freelance consultant working with many major and start-up biotechnology and medical device companies worldwide.

Hartill earned a bachelor’s degree with honors in health sciences from Birmingham University Medical School in England, as well as a master’s degree in management from the University of Wolverhampton in England. Hartill has also earned master’s level credits in sterilization science from Manchester University.

Robert P. Jordheim joined RTI on June 21, 2010 as executive vice president and CFO, and oversees all aspects of finance for the company.

Jordheim has 24 years of progressive corporate finance experience, including 17 years with Medtronic, Inc. Most recently, he served as vice president, finance and business development for Medtronic’s Spinal and Biologics business unit. Previously, he served as vice president, finance for Medtronic’s Surgical Technologies business unit. His tenure with Medtronic also included responsibilities in corporate development and international experience gained through a five-year assignment in Europe. Previous to his tenure at Medtronic, Jordheim served as manager of external reporting at The Fairchild Corporation and an auditor for Deloitte & Touche.

Jordheim earned a bachelor’s degree in business administration from Southern Methodist University and a master’s degree in business administration from the University of Pittsburgh with a concentration in finance.

Dr. Karl Koschatzky is the president of international operations for RTI Biologics’ German subsidiary, Tutogen Medical GmbH. He joined Tutogen in 1993 as the technical director of international operations. Subsequently, Dr. Koschatzky served in many capacities with the company, including the planning and implementation of U.S. operations, leading research and development, and most recently, serving as general manager of German operations. For the 11 years prior to Tutogen, Dr. Koschatzky served as manager of operations, wound care unit, Pfrimmer-Viggo GmbH and scientific manager, wound care business, Lyofil Pfrimmer GmbH.

In his role at RTI Biologics, Dr. Koschatzky oversees all aspects of the company’s international operations based in Neunkirchen, Germany.

Dr. Koschatzky received his Ph.D. from the University of Erlangen-Nurnberg and Diplom-Chemist.

Robby Lane was named assistant to the chairman & CEO/head of global dental for RTI Biologics in October 2009. He joined RTI in March 2006 as director of marketing and subsequently served as general manager of the company’s spine and orthopedics division and vice president, spine and orthopedics. Previous to RTI, Lane spent five years with DeRoyal Industries as vice president of sales and marketing, and prior to that he served as business manager for hips at Stryker Corporation.

In his role with RTI, Lane oversees development and execution of the comprehensive strategy for our global dental business.

A native of Knoxville, Tenn., Lane earned a bachelor’s degree in zoology from the University of Tennessee. He also earned a master’s degree in business administration from the University of Tennessee.

Christie Blakely joined RTI as vice president of sports medicine marketing in August 2009. Her role is to oversee all aspects of the company’s sports medicine marketing, including developing strategic plans for the franchise and directing the priorities of product development. Prior to joining RTI, Blakely spent more than five years at Zimmer Inc., including serving as director of relationship management and surgeon communications, director of U.S. regional marketing for hips and director of global marketing for hips. Previous to her time at Zimmer, Blakely oversaw the hip portfolio at Exactech Inc. Her experience also includes sales and product management at Smith & Nephew. Blakely earned a bachelor’s degree in business administration with a concentration in sales and marketing and a master’s degree in business administration, both from the University of Memphis in Tennessee.

Rod Allen was named vice president, sports medicine distribution for RTI Biologics in February 2008. He joined RTI in September 2003 as director of business development with a focus in sports medicine. Subsequently, Allen served as executive director of U.S. distribution, then as general manager, sports medicine. Prior to joining RTI, Allen spent 10 years in business development and sales and marketing roles in a variety of large high-tech and early-stage medical device companies, most recently as director of business development at UUNET Technologies.

In his current role at RTI Biologics, Allen oversees all aspects of the company’s sports medicine division, including business development, product development, marketing and customer service.

He is a member of the American Orthopaedic Society for Sports Medicine corporate advisory group.

A native of Chicago, Allen earned a bachelor’s degree in political science from Drake University and a master’s degree in business administration with a concentration in finance and marketing, from the University of Maryland – College Park.

Michael LaPrade joined RTI in December 2009 as vice president of surgical specialties, overseeing business and product development for one for the fastest growing areas of the company. LaPrade has more than 16 years experience in sales and marketing for pharmaceutical, medical equipment and medical device companies such as TYCO Healthcare, Boston Scientific and most recently, Gambro Renal Products. Prior to joining RTI, LaPrade served more than two years as vice president of Americas marketing for Gambro’s intensive care division. He earned a bachelor’s degree in business administration with a concentration in marketing at Bryant University in Rhode Island.

Dr. Lenny Archibald was named medical director in January 2003. Prior to joining the company, he served the Centers for Disease Control and Prevention (CDC) for seven years, most recently as acting medical director of the Epidemic Information Exchange and medical epidemiologist in the National Center for Infectious Diseases. His investigation on Clostridium-associated infection related to allograft was published in The New England Journal of Medicine in June 2004 and in Clinical Infectious Diseases in July 2005.

Previous to joining the CDC, Dr. Archibald completed infectious disease and microbiology fellowships at Duke University. He received his undergraduate degree from Harvard University, his medical degree from University College Hospital in London, his doctorate from the University of London and completed postgraduate training in internal and tropical medicine in London, Oxford and Liverpool. In October 2003, Dr. Archibald was named a Fellow of the Royal College of Physicians.

Beverly Bliss joined RTI as the executive director of donor services in February 2005 before becoming vice president of RTI Donor Services in August 2005. She oversees all RTI Donor Services recovery operations, family services, the call center and agency support activities.

Prior to RTI, Bliss served the American Red Cross for 25 years. In January 2005, she was part of the team responsible for divesting the Tissue Services business unit from the American Red Cross.

Bliss holds bachelors’ degrees in biology and health facilities management from Maryville University and a master’s degree in business administration from Webster University. She is a founding member of the Gift of Life Trust fund of South Carolina and has been an active member of the U.S. organ and tissue donation community since 1988.